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Abstract
Background: Recent evidence implicates antibody responses as pivotal damaging factors in spinal cord injury
(SCI)-induced neuroinflammation. To date, only a limited number of the antibody targets have been uncovered,
and the discovery of novel targets with pathologic and clinical relevance still represents a major challenge.
Methods: In this study, we, therefore, applied an unbiased, innovative and powerful strategy, called serological
antigen selection (SAS), to fully identify the complex information present within the antibody repertoire of SCI
patients.
Results: We constructed a high-quality cDNA phage display library derived from human spinal cord tissue to
screen for antibody reactivity in pooled plasma samples from traumatic SCI patients (n = 10, identification cohort).
By performing SAS, we identified a panel of 19 antigenic targets to which the individual samples of the plasma
pool showed antibody reactivity. Sequence analysis to identify the selected antigenic targets uncovered 5 known
proteins, to which antibody reactivity has not been associated with SCI before, as well as linear peptides.
Immunoreactivity against 9 of the 19 novel identified targets was validated in 41 additional SCI patients and an
equal number of age- and gender-matched healthy subjects. Overall, we found elevated antibody levels to at least
1 of the 9 targets in 51 % of our total SCI patient cohort (n = 51) with a specificity of 73 %. By combining 6 of these
9 targets into a panel, an overall reactivity of approximately half of the SCI patients could be maintained while
increasing the specificity to 82 %.
Conclusions: In conclusion, our innovative high-throughput approach resulted in the identification of previously
unexplored antigenic targets with elevated immunoreactivity in more than 50 % of the SCI patients.
Characterization of the validated antibody responses and their targets will not only provide new insight into the
underlying disease processes of SCI pathology but also significantly contribute to uncovering potential antibody
biomarkers for SCI patients.
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Background
Neuroinflammation is a key process in spinal cord injury
(SCI) pathophysiology that can persist for months or
even years after primary trauma. Its strong dual charac-
ter in SCI underscores the need for an in-depth under-
standing of the complex neuroinflammatory processes
[1–3]. While the responses mediated by innate immune
cells and T cells have been extensively studied, the exact
contribution of B cells and the humoral response that is
triggered after SCI remains elusive. In experimental SCI,
B cells accumulated in the injured spinal cord, formed
follicle-like structures and contributed to aggravated tis-
sue damage [4]. B cell-knockout mice displayed a highly
improved neurological recovery and a markedly less
pronounced neuropathology after SCI compared to
wild-type (WT) mice [5]. SCI-induced B cell activation
culminated in the production of pathologic and central
nervous system (CNS)-reactive antibodies which were
released in the blood stream and migrated to the lesion
[4, 5]. Passive transfer of serum antibodies from SCI
mice into naïve/uninjured mice showed that these SCI-
induced antibodies participated in neuroinflammatory
responses and exerted a degenerative effect in the spinal
cord by causing cell death and sustained neurological
dysfunction [4, 5]. A proteomics study on spinal cord
tissue in mice indicated that more than 50 different pro-
teins were targeted by antibodies after SCI; however, up
to now, only glutamate receptor 2/3 and nuclear anti-
gens have been described as antibody targets in SCI
models [4, 6].
In human SCI pathology, increased antibody responses
to a number of CNS proteins (glial fibrillary acidic protein
(GFAP), myelin basic protein (MBP)), glycoproteins
(myelin-associated glycoprotein (MAG)), glycolipids (GM1
gangliosides) and nuclear antigens have been detected.
The antibody titers to several of those myelin components
remained elevated until years after the initial trauma
[7–13]. Interestingly, the titers of these antibodies seemed
to correlate with clinical parameters (e.g. SCI complica-
tions) [7, 8, 10]. Identification of the full spectrum of anti-
genic targets of the SCI-induced antibody responses is
indispensable to develop passive and active antibody-
based therapeutics or diagnostic and prognostic agents.
To date, only antibody responses to target antigens de-
scribed in other CNS disorders have been investigated in
SCI pathology. This hypothesis-driven approach yielded
only limited success in identifying clinically relevant
antibody responses. The heterogeneous nature of the
SCI population further underscores the importance of
an innovative and unbiased approach, to fully explore
the complex information present in the antibody reper-
toire of SCI patients. Serological antigen selection (SAS)
is a powerful high-throughput method based on comple-
mentary DNA (cDNA) phage display and subsequent
selection on patient antibodies which enables the identi-
fication of a broad profile of antigenic targets [14–16].
By using a cDNA phage display library derived from the
target tissue, a disease-relevant system that is fully repre-
sentative for the heterogeneity present within the target
tissue is created. This approach allows the identification
of not only known proteins but also unknown or
uncharacterized proteins. SAS has been successfully ap-
plied in our lab to identify an elaborate panel of novel
relevant antibody responses for various diseases, such as
multiple sclerosis, clinically isolated syndrome and
rheumatoid arthritis [17–19]. We have demonstrated
not only the pathologic in vivo relevance of these anti-
body responses but also their diagnostic and prognostic
potential [20–22].
In the present study, we constructed a high-quality
cDNA expression library from human spinal cord tis-
sues which allowed rapid isolation of novel antigenic
targets and identified generic antibody responses by
using plasma samples from SCI patients. Subse-
quently, detailed serological characterization of these
antibody responses was assessed in SCI patients and
healthy controls.
Methods
Patient samples
Peripheral blood was collected from traumatic and patho-
logic SCI patients in Jessa Hospital (Hasselt, Belgium),
University Hospitals Leuven (Leuven, Belgium), Adelante
Rehabilitation Centre (Hoensbroek, The Netherlands),
Hospital East-Limburg (Genk, Belgium), Antwerp University
Hospital (Edegem, Belgium), Radboud University Medical
Centre (Nijmegen, The Netherlands) and Academic Hospital
Maastricht and General Hospital Turnhout (Turnhout,
Belgium). Samples of traumatic SCI patients were taken at
hospitalization (T0) or 3 weeks after injury (T1). Samples
of pathologic SCI patients (e.g. stenosis, spinal disc hernia-
tion, compression caused by bleeding) were collected pre-
operatively (T0) and 3 weeks after surgery (T1). Patients
with pre-existing autoimmune disorders were excluded
from the study. Written informed consent was acquired
from all participants after approval by the Medical ethics
committee Hospital East Limburg (B371201317091), Ade-
lante (54-14/CK/JM) and Academic Hospital Maastricht
(METC13-4-079). Blood samples were centrifuged for
10 min at 400g. Plasma was collected and centrifuged for
10 min at 1500g. After processing, plasma samples were
aliquoted and stored at −80 °C. Samples were processed
and stored in collaboration with the University Biobank
Limburg (UBiLim) and Biobank University Hospitals Leu-
ven. A total of 51 SCI patients and 49 age- and gender-
matched healthy controls were involved in the study.
Plasma samples from healthy controls were collected via
UBiLim.
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Construction of a hSC cDNA phage display library
Commercially obtained poly A+ RNA (size range of 0.2–
10 kb, Clontech, Saint-Germain-en-Laye, France) from
spinal cord tissue of 18 Caucasians (ages 25–63 years)
was converted to double-stranded cDNA with EcoRI
and XhoI adapters by using the Superscript Choice
System for cDNA synthesis kit (Life Technologies, Gent,
Belgium) as described previously [23]. Purified cDNA
inserts were directionally ligated into our pVI phage
display vectors, pSPVIA, pSPVIB and pSPVIC, each
representing 1 of 3 different reading frames [16].
Ligation mixtures were used to transform Escherichia
coli (E.coli) TG1 cells (Lucigen, Middleton, USA) by
electroporation to obtain human spinal cord (hSC)-
pSPVIA, hSC-pSPVIB and hSC-pSPVIC libraries.
Serological antigen selection procedure
The serological antigen selection (SAS) procedure was
performed as described previously [16, 19]. In brief, an
immunotube (Nunc, Roskilde, Denmark) was coated
overnight at 4 °C with 10 μg/ml rabbit anti-human im-
munoglobulin G (IgG, Dako, Glostrup, Denmark) in
coating buffer (0.1 M sodium hydrogen carbonate, pH
9.6). After washing with 0.1 % (v/v) phosphate-buffered
saline-Tween20 (PBS-T, 50 mM Tris, 150 mM sodium
chloride, pH 7.5) and PBS, the immunotube was blocked
with 2 % (w/v) skimmed milk powder in PBS (MPBS) for
2 h at room temperature (RT). Plasma samples of 10
traumatic SCI patients were pooled and pre-adsorbed
against E. coli and phage components, as described pre-
viously [16]. For the first selection round, equal numbers
of phage particles from each hSC cDNA phage display
library (hSC-pSPVI-A, hSC-pSPVI-B and hSC-pSPVI-C)
were pre-incubated with the pre-adsorbed SCI plasma
pool in 2 % MPBS for 1.5 h at RT on a rotating platform
[24]. After washing the immunotube, the pre-incubated
phage-plasma mix was transferred to the coated tube on
a rotating platform, followed by standing conditions at
RT. Non-bound phage were removed by extensive wash-
ing of the immunotube with 0.1 % PBS-T and PBS.
Bound phage were eluted by adding 100 mM triethyla-
mide (Sigma-Aldrich, Bornem, Belgium) to the immuno-
tube for 10 min on a rotating platform and neutralized
with 1 M Tris-HCl (pH 7.4). The output of each selec-
tion round was amplified by infection of E. coli TG1
bacteria and plated on ×2 YT agar plates containing
ampicillin and glucose (16 g/l bacto-tryptone, 10 g/l
yeast extract, 5 g/l NaCl, 15 g/l bacto-agar, ampicillin at
100 μg/ml, and glucose at 2 %). Five consecutive selec-
tion rounds were performed. To identify enriched cDNA
clones, individual colonies were selected and insert cDNA
fragments were amplified with vector primers binding ad-
jacent to the cDNA insert followed by restriction enzyme
digestion (BstNI (Roche Diagnostics, Vilvoorde, Belgium)
and NspI (NEB, Leiden, The Netherlands)). Enriched
cDNA products representing identical cDNA clones were
selected and identified by sequencing of the corresponding
cDNA phage insert. Amino acid sequences of identified
clones were compared to public protein databases of the
National Center for Biotechnology Information (NCBI)
with BLAST analysis.
Phage ELISA
Antibody reactivity levels of individual plasma samples
against selected phage clones were measured by phage
enzyme linked immunosorbent assay (ELISA). Ninety-
six-well flat-bottom plates (Greiner Bio-One, Wemmel,
Belgium) were coated overnight at 4 °C with 5 μg/ml
anti-M13 antibody (GE Health care, Diegem, Belgium)
in coating buffer. Plates were washed twice with PBS
and blocked with 5 % MPBS for 2 h at 37 °C, while
shaking. After washing three times with 0.1 % PBS-T
and once with PBS, polyethylene glycol-purified phage
displaying the candidate antigen (7 × 1011 colony-
forming units/ml) or empty phage (negative control)
were added and incubated for 1 h at 37 °C under static
conditions followed by 30 min at RT, while shaking.
Plates were washed, and plasma samples (1/100 in 5 %
MPBS) were incubated for 1 h at 37 °C under static
conditions followed by 30 min at RT, while shaking.
Washing steps were repeated, and horseradish pero-
xidase human IgG-Fc fragment cross-adsorbed antibody
(1/50,000, Bethyl laboratories, Montgomery, USA) was
added for 1 h shaking at RT. 3,3′,5,5′-Tetramethyl-
benzidine dihydrochloride (TMB, Thermo Scientific,
Erembodegem, Belgium) solution was added after
washing the plates, and the reactions were incubated
in the dark for 11 min. The colour reaction was
stopped by adding 1.8 N H2SO4. Optical density (OD)
signals were measured at 450 nm in a Tecan plate
reader (Tecan, Männedorf, Switzerland). Samples were
considered positive when the general reactivity (OD
(specific phage)/OD (empty phage)) was higher than
1.5 and the OD-value of a specific signal was above
0.1. Samples were tested in duplicate in a single
ELISA experiment, and experiments were performed
independently for at least two times. Polyreactive
samples (reactive to the empty phage) were excluded
from the analysis.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
6 XML. Fisher’s exact test was applied for the analysis of
associations between the presence of antibody reactivity
directed to particular antigenic targets or panels of tar-
gets and SCI patients. A p value of <0.05 was considered
statistically significant.
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Results
Antibody profiling of SCI plasma samples using SAS
A high-quality hSC cDNA phage display library was gen-
erated from human spinal cord tissue of 18 Caucasians.
Human spinal cord cDNA fragments were cloned into
the pVI phage display vectors in three reading frames,
resulting in a total library size of 2.44 × 106 independent
clones. The spinal cord cDNA inserts ranged from 350
to 2000 base pairs. Details of the performed quality con-
trols are described in [23]. Altogether, these results
showed that the hSC cDNA phage display library had a
high quality and diversity. Subsequently, this hSC cDNA
phage display library was screened for antibody reactivity
using a plasma pool consisting of 10 randomly selected
traumatic SCI patients (identification cohort; mean age
48 years (range from 27 to 85 years); Table 1). In the iden-
tification cohort, both samples collected at hospitalization
(i.e. within 48 h after traumatic injury; T0) and 3 weeks
after injury (T1) were included. The majority of the
patients were men (9/10) and had a cervical level injury
(6/9). Both injury severity and type (compression, contu-
sion, fracture or laceration) were highly diverse within the
pool. By using a heterogeneous plasma pool, the general
patient population was represented and the detection of
patient-specific immunoreactivity was limited.
To analyse the overall antibody reactivity profile in SCI
patients, SAS was used. Five consecutive selection rounds
were performed. After characterization of the selection out-
put, a total of 38 enriched phage clones were selected
which represent putative antigenic targets present after SCI.
Antibody reactivity is increased in plasma of traumatic
SCI patients
To confirm that the enriched phage clones were selected
based on specific interactions with SCI patient antibodies
and to characterize the reactivity toward the identified
clones, a pilot screen was performed on the individual
plasma samples from the 10 traumatic SCI patients used
in the SAS procedure (identification cohort) and an equal
number of age- and gender-matched healthy controls. As
shown in Fig. 1, 19 phage clones showed antibody reactiv-
ity in 9 of the 10 traumatic SCI plasma samples, while no
or low reactivity was detected in healthy controls, which
demonstrates that SCI-related antibodies were identified
(Fig. 1). The remaining phage clones displayed no reactiv-
ity in traumatic SCI patients or reactivity in the control
samples. SCI-reactive antigenic targets were annotated an
UH.SCI.number (Hasselt University, SCI, clone number).
Based on the level and abundance of the antibody re-
sponses, our results show that traumatic SCI patients have
an increased reactivity toward the selected antigenic tar-
gets compared to the healthy control group.
Identity of antigens targeted by SCI-related antibodies
To gain insight into the antibody responses that are
present after SCI, the targets of the selected antibody re-
sponses were identified using sequencing and the amino
acid sequences of the 19 antigenic targets were com-
pared to public protein databases using BLAST analysis
of NCBI (Table 2). Five of the selected antigenic targets
(UH.SCI.2, UH.SCI.5, UH.SCI.6, UH.SCI.7 and UH.SCI.19)
encoded parts of known proteins: 26S proteasome non-
ATPase regulatory subunit 4 (PSMD4), glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), myeloma-
overexpressed gene 2 (MYEOV2), protein S100-B (S100B)
and adipocyte enhancer-binding protein 1 (AEBP1). The
remaining antigenic targets resulted from the expression of
novel cDNA sequences, out of frame expression of known
cDNAs or normally untranslated messenger RNA (mRNA)
regions (e.g. 3′UTR regions). These expressed peptides
Table 1 Characteristics of traumatic SCI patients used for the SAS procedure (identification cohort)
Patient Time of sampling (T)a Age (years) Genderb Location of injuryc Type of tSCId
SCI.1 T0 27 M T5 Laceration
SCI.2 T0 29 M T6-10 Fracture
SCI.3 T0 37 M C4-6 Contusion
SCI.4 T0 43 M C4-5 Contusion
SCI.5 T0 54 M C6 Fracture
SCI.6 T0 67 M NAe Compression
SCI.7 T1 33 M C6-T2 Contusion
SCI.8 T1 29 M C4 Contusion
SCI.9 T1 73 F C1 Compression
SCI.10 T1 85 M C6 Contusion
aT0 at hospitalization, T1 3 weeks after injury
bF female, M male
cC cervical, T thoracic
dtSCI traumatic spinal cord injury
eNot available
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likely form epitopes which structurally mimic in vivo anti-
gens (mimotopes) and showed partial homology to proteins
which might be implicated in brain disorders (e.g. ras/Rap
GTPase-activating protein (SYNGAP1), to different known
proteins (e.g. zinc finger protein 148 (ZN148) and receptor
tyrosine-protein phosphatase eta (PTPRJ)) and to proteins
with unknown function (e.g. transmembrane protein 236
(TMEM236)) [25]. Upon close examination of the different
targets, it becomes clear that the identified antigenic targets
are highly diverse with regard to their size (4 to 120 amino
acids), sequence composition and amino acid characteris-
tics (hydrophobic, polar or charged). This is also illustrated
by the reactivity profile detected in an individual traumatic
SCI patient (SCI.4), who shows specific and strong reactiv-
ity toward several targets (UH.SCI.5, UH.SCI.7, UH.SCI.12-
15 and UH.SCI.19) which are diverse in sequence and
structure characteristics. Altogether, our results demon-
strate that antibody responses to a broad range of antigenic
targets are present in SCI patients.
Validation of the identified antibody responses in SCI
patients
Next, we addressed whether antibody reactivity toward
the 19 novel antigenic targets was also present in a
larger confirmatory cohort of SCI patients. Therefore,
we screened 41 additional SCI patients from which sam-
ples collected within the same time range as the identifi-
cation cohort samples were available. This allowed us to
validate the identified antibody responses in a similar
phase after injury. After large-scale screening of the SCI
patient samples and age- and gender-matched healthy
controls, immunoreactivity against 9 of the 19 novel
identified targets was validated. For 19/41 (46 %)
additional SCI patients, antibody reactivity was detected
toward at least 1 of the 9 targets. The remaining targets
were excluded because patient reactivity could not be
confirmed in our validation cohort or high reactivity was
detected in control samples.
Our total SCI cohort (identification and validation co-
hort) consisted of 51 SCI patients (82 % males, mean
age 57 ± 16 years) and contained both traumatic and
pathologic SCI patients. Furthermore, 49 age- and
gender-matched controls (65 % males, mean age 55 ±
17 years) were included in the screening (Table 3). Of
the total SCI cohort, 26/51 (51 %) patients showed anti-
body reactivity to at least 1 of the 9 validated targets
(Table 4). The frequency of antibody reactivity against
the individual targets within the SCI patients ranged
Fig. 1 Increased antibody reactivity in plasma of traumatic SCI patients. Antibody reactivity toward the identified targets is increased in the
individual traumatic SCI samples used in the SAS procedure (n = 10) compared to healthy controls (n = 9). Samples were considered positive
when the general reactivity (OD (specific phage)/OD (empty phage)) was higher than 1.5 and the specific signal was above 0.1. Antibody levels in
positive samples are shown in a grey scale. Low antibody levels are indicated in light grey (ratio reactivity (OD (specific phage)/OD (empty phage))
is 2); high antibody levels are indicated in dark grey (ratio reactivity (OD (specific phage)/OD (empty phage)) ranged from 12 to 16). Samples were
analysed in duplicate in a single ELISA experiment, and experiments were performed independently for at least 2 times
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from 4 to 20 %. The highest reactivity and SCI specificity
was demonstrated using a panel of 6 targets. Immunore-
activity toward this SCI patient-associated antigen panel
could be detected in approximately half of the SCI
patients (47 %) with an associated specificity of 82 %
(p = 0.00145, Table 4). For 1 of the individual antigenic tar-
gets, UH.SCI.9, a significant association was found be-
tween the presence of antibody reactivity and SCI patients
(p = 0.0134; overall reactivity 12 %; specificity 100 %,
Table 4). Interestingly, while only traumatic SCI patients
were included in the selection of SCI-related antibody re-
sponses, also 46 % of the pathologic SCI patients showed
increased immunoreactivity toward this panel of 6 novel
identified targets (Table 4).
Whether or not the presence of these identified anti-
body responses after SCI was determined by the time
point of sampling, we compared the antibody reactivity
in patient samples collected at hospitalization (T0) and
at 3 weeks after injury (traumatic SCI) or surgery
(pathologic SCI) (T1) (Fig. 2). Within the SCI cohort,
both traumatic and pathologic SCI patients showed anti-
body reactivity at hospitalization and 3 weeks after injury
or surgery. Notably, most antibody-positive patients ex-
hibit reactivity at both time points of sampling.
Altogether, immunoreactivity toward 9 novel identified
antigenic targets was validated in both traumatic and
pathologic SCI patients, which highlights the relevance
of these novel identified antibody responses and their
targets in inflammatory mechanisms present after dam-
age to the spinal cord.
Discussion
In the present study, the antibody signature of SCI pa-
tients was explored by using a powerful and unbiased
high-throughput strategy, called SAS. By pooling plasma
of 10 patients with highly diverse lesion characteristics
(location, type and severity of the lesion), we analysed
the general antibody reactivity profile present in the het-
erogeneous SCI patient population. Our innovative and
unbiased approach resulted in the identification of 19
Table 2 Target identity of the SCI-related antibody responses
Clone Translated cDNA product Size (amino acids) Homology on protein level
Coding
UH.SCI.2 TEEDDYDVMQDPEFLQSVLENLPGVDPNNEAIRNAMGS
LASQATKDGKKDKKEEDKK*
57 (56/56) 26S proteasome non-ATPase regulatory subunit 4
(PSMD4)
UH.SCI.5 HRVVDLMAHMASKE* 14 (13/13) glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
UH.SCI.6 TFPEGAGPYVDLDEAGGSTGLLMDLAANEKAVHADFFN
DFEDLFDDDDIQ*
50 (49/50) myeloma-overexpressed gene 2 protein (MYEOV2)
UH.SCI.7 HEFFEHE* 7 (7/7) protein S100-B (S100B)
UH.SCI.19 PVETYTVNFGDF* 12 (11/11) adipocyte enhancer-binding protein 1 (AEBP1)
Non-coding
UH.SCI.1 IKTVTSQ* 7 (6/7) transmembrane protein 236 (TMEM236)
UH.SCI.3 TNNFITSNKN* 10 (6/6) calcium-activated chloride channel regulator 2 (CLCA2)
UH.SCI.4 PLKDIIDNI* 9 (6/6) Di-N-acetylchitobiase precursor (CTBS)
(6/8) poly(A)-specific ribonuclease PARN (PARN)
(6/6) TBC1 domain family member 2B (TBC1D2B)
UH.SCI.8 NSSKTYVGTSDKVQTPSRDLGCPLGSHCSLSLLT* 34 No significant similarity found
UH.SCI.9 NSELLSNKSALHKFIKYAFWI* 21 (12/19) E3 ubiquitin-protein ligase HACE1 (HACE1)
UH.SCI.10 PFFTVPIPRPGA* 12 (8/8) F-box only protein 42 (FBXO42)
UH.SCI.11 EFFDNSRKVDD* 11 (6/8) Ras/Rap GTPase-activating protein SynGAP (SYNGAP1)
UH.SCI.12 NSKHSLKS* 8 (6/7) zinc finger protein 148 (ZNF148)
UH.SCI.13 EDKT* 4 (4/4) Tax1-binding protein 3 (TAX1BP3)
UH.SCI.14 TQEGAGSERGVITTF* 15 (10/14) receptor-type tyrosine-protein phosphatase eta (PTPRJ)
UH.SCI.15 TEGKEQERSDKDE* 13 (7/9) Espin (ESPN)
UH.SCI.16 QGEDKISVY* 9 (6/6) Midasin (MDN1)
UH.SCI.17 NSLHSLLGQKNND* 13 (10/13) Zinc finger protein 28 (ZNF28)
UH.SCI.18 QRLFRQSSSQELLGCGSKTLMGGEGWLLEEGRSQTGQ
TVLLTPSPAQRALPLWPLLQTPALTHTPLGLHSFALKDL
PKSPFPCLASPLRRERYLQNWVGGMSMNCPSIWDMLH
QSERENK
120 No significant similarity found
*stop codon
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distinct antigenic targets with increased reactivity in SCI
patients compared to healthy controls. We confirmed re-
activity toward 9 of the 19 targets in an additional co-
hort of 41 SCI patients, including both traumatic and
pathologic SCI patients, and an equal number of age-
and gender-matched healthy controls. Antibody reactiv-
ity against these 9 novel targets was found in 51 % of the
total SCI patient cohort. By combining 6 of these 9 tar-
gets into a panel, an overall reactivity of approximately
50 % could be maintained while increasing the specificity
to 82 %.
We here report immunoreactivity toward various
novel antigenic targets in SCI patients, identified via a
powerful unbiased approach. A proteomics study using
spinal cord tissue already indicated that over 50 distinct
antigenic targets are present after SCI in mice [4, 6]. By
using a tissue-specific cDNA library containing cDNA
sequences encoding proteins with a nervous system-
specific expression pattern or proteins involved in
pathologic processes triggered after SCI, we created a
relevant strategy to identify novel antibody targets in
SCI [23]. Our results indicate that this highly diverse
antibody profile is also present in SCI patients. Further-
more, we are the first to thoroughly address the identity
of the various antigenic targets after SCI. Previously,
hypothesis-driven studies only demonstrated elevated
antibody responses toward MBP, MAG, GFAP, GM1
ganglioside and galactosylceramidase in sera of SCI pa-
tients, and we now extend the antibody profile with re-
sponses directed against S100B, GAPDH, PSMD4,
AEBP1 and MYEOV2 [7–13]. The first novel identified
target, S100B, is a dimeric calcium-binding protein local-
ized predominantly in astroglial and Schwann cells, and
increased levels of this protein have been found in CSF
and serum of SCI patients [26–29]. While antibody re-
sponses directed against S100B were shown in CNS
pathologies such as traumatic brain injury (TBI), they
have not been reported in SCI patients before [30, 31].
S100B protein was detected in a very early stage after
SCI with peak levels detectable already 6 h after injury
[32, 33]. Interestingly, in this study, antibody responses
toward UH.SCI.7 (S100B) were already present in sam-
ples taken within 48 h after injury. Target UH.SCI.5
partly encodes GAPDH which is a well-studied
Table 3 Characteristics of the study populations
Cohort Time of sampling (T)a Mean age (in years) Gender (F/M)b AISc Location of injuryd tSCI/pSCI ratioe
Patients
n = 51
T0–T1 57 9/42 A-E C-S 25/26
Healthy controls
n = 49
– 55 17/32 – – –
aT0 at hospitalization, T1 3 weeks after injury or surgery
bF female, M male
cAmerican Spinal Injury Association Impairment Scale
dC cervical, S sacral
etSCI traumatic spinal cord injury, pSCI pathologic spinal cord injury
Table 4 Antibody reactivity in the SCI cohort and age- and gender-matched healthy controls
Clone Identification cohort
(n = 10)
Validation cohort
(n = 41)
Total cohort (n = 51) HCc (n = 49) Fisher’s exact test
(p value)d
tSCIa (n = 25) pSCIb (n = 26) Total (n = 51)
UH.SCI.1 1/10 (10 %) 3/41 (7 %) 2/25 (8 %) 2/26 (8 %) 4/51 (8 %) 2/49 (4 %) ns
UH.SCI.2 1/10 (10 %) 4/41 (10 %) 2/25 (8 %) 3/26 (12 %) 5/51 (10 %) 1/49 (2 %) ns
UH.SCI.7 2/10 (20 %) 2/41 (5 %) 2/25 (8 %) 2/26 (8 %) 4/51 (8 %) 2/49 (4 %) ns
UH.SCI.8 2/10 (20 %) 1/41 (2 %) 2/25 (8 %) 1/26 (4 %) 3/51 (6 %) 2/49 (4 %) ns
UH.SCI.9 1/10 (10 %) 5/41 (12 %) 3/25 (12 %) 3/26 (12 %) 6/51 (12 %) 0/49 (0 %) 0.0134
UH.SCI.11 3/10 (30 %) 7/41 (17 %) 5/25 (20 %) 5/26 (19 %) 10/51 (20 %) 5/49 (10 %) ns
UH.SCI.12 1/10 (10 %) 1/41 (2 %) 1/25 (4 %) 1/26 (4 %) 2/51 (4 %) 0/49 (0 %) ns
UH.SCI.13 1/10 (10 %) 1/41 (2 %) 1/25 (4 %) 1/26 (4 %) 2/51 (4 %) 1/49 (2 %) ns
UH.SCI.15 1/10 (10 %) 4/41 (10 %) 3/25 (12 %) 2/26 (8 %) 5/51 (10 %) 1/49 (2 %) ns
Total cohort 7/10 (70 %) 19/41 (46 %) 13/25 (52 %) 13/26 (50 %) 26/51 (51 %) 13/49 (27 %) 0.0073
Panel of 6 targets (bold) 6/10 (60 %) 18/41 (44 %) 12/25 (48 %) 12/26 (46 %) 24/51 (47 %) 9/49 (18 %) 0.00145
atSCI traumatic spinal cord injury
bpSCI pathologic spinal cord injury
cHC healthy control
dns not significant
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multidimensional protein involved in the homeostatic
regulation and is often referred to as a “housekeeping”
protein [34, 35]. In stroke models, nuclear GAPDH cas-
cades are triggered leading to posttranscriptional modifi-
cations and allowing GAPDH to play a crucial role in
brain damage [35, 36]. Because of the multifunctional in-
volvement of GAPDH in the brain, it is not surprising
that GAPDH might play a role in SCI pathology [35, 36].
PSMD4 is a non-ATPase subunit of the proteasomal 19S
regulator which plays a key role in the recognition and
processing of ubiquitylated proteins for proteolysis, and
AEBP1 may have a proinflammatory function and is in-
volved in apoptosis and cell survival [37, 38]. The func-
tion of MYEOV2, on the other hand, is still unknown.
Furthermore, 14 peptide sequences were identified
which resulted from the expression of novel cDNA se-
quences, out of frame expression of known cDNAs or
untranslated mRNA regions (e.g. 3′UTR regions) and
probably comprise mimotopes. Overall, we identified
antibody responses against a broad panel of targets
which further underlines the strength of using an un-
biased approach such as SAS.
During immune maturation, B cells are not exposed to
the variety of unique CNS antigens expressed on
neurons, oligodendrocytes, microglia and astrocytes
causing a lack of tolerance against these CNS-specific
proteins. Although evidence suggests that the blood-
spinal cord barrier (BSCB) is more permeable than the
blood-brain barrier (BBB), under normal conditions, an
intact blood-CNS barrier protects neurons and glial cells
from antibodies that cross-react with neurological tissue
[39]. However, when the blood-CNS barrier is damaged,
these circulating antibodies can infiltrate the CNS with
the potential destruction of the neurologic tissue. A re-
cent study showed that the lack of S100B compromises
the BBB and allows access of CNS-reactive antibodies to
the brain which generates pathological changes [40].
Upon SCI, the BSCB permeability is compromised as
long as 56 days [41]. Antibodies against S100B might
however prolong BSCB permeability resulting in a con-
tinued neuroinflammatory response. Yet, even after re-
constitution of BSCB integrity, processes such as
adsorptive endocytosis, active transport across the
blood-CNS barrier and local antibody production can re-
sult in antibody accumulation in the injured spinal cord
[4].
The antibody responses toward the novel identified
targets were detected both in samples collected at
Fig. 2 Antibody reactivity in SCI samples collected at hospitalization and 3 weeks after injury or surgery. Immunoreactivity toward the panel of 6
novel identified antigenic targets is found in samples collected at hospitalization (collected within 48 h and maximum 4 days after injury, T0) and
3 weeks after injury or surgery (T1). Antibody reactivity is illustrated as the ratio (OD (specific phage)/OD (empty phage)). Samples were
considered positive when the general reactivity (OD (specific phage)/OD (empty phage)) was higher than 1.5 and the specific signal was above
0.1. Samples were analysed in duplicate in a single ELISA experiment, and experiments were performed independently for at least 2 times
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hospitalization and 3 weeks after injury or surgery. The
mechanisms and different phases of antibody production
after SCI have been investigated in SCI mouse models
[4, 5]. It was suggested that after SCI and damage of the
blood spinal cord barrier, CNS antigens are released into
the bloodstream and drain into peripheral lymphoid tis-
sues where they encounter the cells of the adaptive im-
mune system. Newly formed IgG antibodies are typically
formed 3 weeks after the insult [42]. The formation of
new antibodies in SCI is supported by Ankeny et al. who
showed that serum IgM levels are increased in SCI mice
during the first 2 weeks after injury, while serum IgG2a
levels are delayed until week 2 and remained elevated up
to 42 days post injury [4]. Besides newly formed immune
responses, resting or memory B cells can become
primed or re-activated by cognate antigens or polyclonal
stimuli which has been suggested as a mechanism for
antibody responses to CNS proteins in SCI pathology.
Our results imply that both newly formed antibody re-
sponses and molecular mimicry mechanisms might be
relevant in human SCI pathology.
Interestingly, while only traumatic SCI patients were
used in the identification of the novel antibody re-
sponses, increased reactivity toward the identified anti-
genic targets was also evident in nearly half of the
pathologic SCI patients. While traumatic SCI is an acute
event, pathologic SCI is often a more chronic process.
Since antibodies are stable, become amplified in the im-
mune response and have a long half-life, their presence
over time in pathology is not unexpected and highlights
the relevance of these antibody responses in common in-
flammatory processes that are triggered after injury to
the spinal cord.
Besides the potential relevance of the identified targets
and their corresponding antibody responses in SCI
pathophysiology, the discovery of these novel SCI-
related antibody responses is also highly relevant from a
clinical viewpoint. We here report individual antigenic
targets with an overall reactivity varying from 4 to 20 %,
and with high specificity ranging from 90 to 100 %,
which are comparable to the previously reported anti-
body reactivity toward GM1 gangliosides, GFAP, MAG
and MBP [7–9, 11, 12]. One of our novel identified anti-
genic targets (UH.SCI.9) was significantly associated
with SCI patients. By combining 6 antigenic targets in a
SCI patient-associated panel, we found relevant immu-
noreactivity in 47 % of the SCI patients with a 82 % spe-
cificity. Multiplexing of inflammatory biomarkers in SCI
pathology has been shown to be a valuable strategy to
significantly improve the sensitivity rate while maintain-
ing a high specificity [28]. Previous studies showed that
enhanced antibody levels correlated with complications
in SCI patients [7, 8, 10]. So far, association of the novel
antibodies with clinical parameters could not be
determined as our SCI patient population is heteroge-
neous and a limited sample size was screened. Gender-
related influences on the outcome after SCI have been
reported with a better recovery in females. The im-
proved recovery has, at least partly, been attributed to
the regulation of the SCI-induced neuroinflammatory re-
sponse by sex hormones [43, 44]. In our cohort, analyz-
ing the validated antibody responses based on gender
did not show any sex-related differences in antibody re-
activity against the novel identified targets. Still, as anti-
bodies have been suggested to represent better
biomarkers than their antigen counterparts, and we find
increased antibody responses already very early after the
injury, the investigation of their potential as a prognostic
biomarker for SCI patients is highly desirable [45–47].
Conclusions
In summary, the antibody reactivity profile after SCI in
humans was explored by using an unbiased and power-
ful high-throughput technology based on phage display,
which resulted in the identification of 9 novel antigenic
targets with elevated immunoreactivity in SCI patients
compared to healthy controls. By combining 6 of these 9
antigenic targets into a panel, an overall reactivity of
nearly 50 % could be detected with a specificity of 82 %.
Further characterization of both the SCI-related anti-
body responses and the corresponding targets will pro-
vide more insight into the role of the humoral immune
component within SCI-induced neuroinflammation and
their clinical relevance.
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